Tobacco Industry Targets Women in Asia
A cigarette vendor in Manila sells a pack of 20 sticks for less than a dollar. Credit: Kara Santos/IPSBy Wendell Balderas and Mary AssuntaBANGKOK, Thailand, Mar 14 2019 (IPS) International Women’s Day on 8 March recognized and celebrated the progress women are making globally. The day also acknowledged the risks, exploitation and suffering many continue to endure. The Southeast Asia Tobacco Control Alliance (SEATCA) puts the spotlight on the tobacco industry’s marketing tactics targeting women and girls especially in Asia to market its deadly products. While smoking prevalence among females remains relatively ...
Source: IPS Inter Press Service - Health - March 14, 2019 Category: International Medicine & Public Health Authors: Wendell Balderas and Mary Assunta Tags: Aid Development & Aid Economy & Trade Environment Featured Global Headlines Health TerraViva United Nations Women's Health Source Type: news

El Camino Hospital first in California to offer new treatment for severe COPD/emphysema
(Pulmonx) El Camino Hospital today announced it is the first hospital in California to have successfully performed the new and recently Food and Drug Administration (FDA) approved lung valve treatment for patients with severe COPD/emphysema, an incurable lung disease that causes extreme breathing difficulty and constant discomfort for patients. The Zephyr ® Endobronchial Valve treatment represents a major advancement because it is the first minimally invasive procedure to help emphysema sufferers breathe easier without major surgery. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 12, 2019 Category: International Medicine & Public Health Source Type: news

NIST proposes new universal standard for CT calibration
Scientists at the National Institute of Standards and Technology have proposed a new universal standard for calibrating computed tomography devices that they claim may improve comparisons between scans from various devices. The newly released calibration approach was outlined in a research paper recently published in the academic journal PLOS One, the NIST said in a press release. “If the technical community could agree on a definition, then the vendors could create measurements that are interchangeable. Right now, calibration is not as thorough as it could be. Better comparisons among scanners might allow us to es...
Source: Mass Device - March 4, 2019 Category: Medical Devices Authors: Fink Densford Tags: Featured Imaging National Institute of Standards and Technology Source Type: news

Nuvaira Raises $79M for COPD Treatment Device
Nuvaira has raised $79 million to help develop a treatment for Chronic Obstructive Pulmonary Disease (COPD). The Minneapolis, MN-based company said U.S. Venture Partners, with Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation joined the round, along with all of Nuvaira's existing investors: Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, Versant Ventures, Vertex Venture Holdings, and Windham Venture Partners. Nuvaira is developing a Lung Denervation System that addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and as...
Source: MDDI - February 11, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

E-Cigs More Effective Than Nicotine Replacements in Helping Smokers Quit, Study Shows
A study published in the New England Journal of Medicine Wednesday put to the test a major claim made by e-cigarette makers when the devices first emerged: that electronic cigarettes, which don’t burn tobacco but do still provide a hit of nicotine, can help cigarette smokers to kick the habit. In a rigorous study pitting the battery-powered e-cigs against nicotine replacement therapies like nicotine gums, lozenges, sprays and patches, the researchers found that e-cigs helped smokers to remain abstinent for one year at nearly twice the rate as those using nicotine replacement options. Among 886 smokers who were random...
Source: TIME: Health - January 31, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized e-cigs health onetime Smoking Source Type: news

Olympus announces Spiration bronchial valve launch
The Spiration valve is an umbrella-shaped device that a health provider places in a targeted airway of the lung during a short bronchoscopic procedure. [Image courtesy of Olympus]Olympus’  Spiration bronchial valve for the treatment of severe emphysema is now available on the market, the company  (TYO:7733) said today. The announcement came a little over a year after FDA approval of Spiration, which was designated as a breakthrough medical device. Spiration also has regulatory approval in the E.U., Australia and New Zealand. Get the full story on our sister site Medical Design & Outsourci...
Source: Mass Device - January 22, 2019 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News News Well emphysema Olympus Source Type: news

Mayo Clinic Q and A: Rare, inherited risk factor can result in emphysema and liver damage
DEAR MAYO CLINIC:?A family friend was recently diagnosed with emphysema, but he never smoked and was told that his condition was caused by alpha-1. What is this, and how is it diagnosed? ANSWER: Emphysema?is one of a group of lung diseases, including chronic bronchitis, that make up chronic obstructive pulmonary disease, or COPD. Tobacco smoking [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 15, 2019 Category: Databases & Libraries Source Type: news

Ask How Do You Get Emphysema
How Do You Get Emphysema? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 14, 2019 Category: General Medicine Source Type: news

Daily Vitamin D Could Be a Lifesaver for Some COPD Patients
FRIDAY, Jan. 11, 2019 -- Deadly lung attacks may be averted in some COPD patients with a daily dose of vitamin D, new research suggests. Chronic obstructive pulmonary disease, or COPD, includes a number of lung conditions, including emphysema and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 11, 2019 Category: General Medicine Source Type: news

Penn Highlands Healthcare first in the region to offer first FDA-approved lung valve for patients with severe COPD/emphysema
(Pulmonx) Penn Highlands Healthcare is the first medical facility in the region to offer bronchoscopic lung volume reduction using the first lung valve approved by the US Food and Drug Administration for helping emphysema patients breathe easier without major surgery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 8, 2019 Category: International Medicine & Public Health Source Type: news

Chronic obstructive pulmonary disease in over 16s diagnosis and management NICE guideline [NG115]
This guideline covers diagnosing and managing chronic obstructive pulmonary disease (COPD) in people aged 16 and older, which includes emphysema and chronic bronchitis. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer. It was published in December 2018. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 20, 2018 Category: Consumer Health News Source Type: news

Olympus wins FDA nod for Spiration bronchial valve
Olympus (TYO:7733) said yesterday that it won FDA approval for its Spiration Valve System intended to treat severe emphysema, which was designated as a breakthrough medical device. The Spiration Valve is an umbrella shaped device intended to improve breathing by blocking airflow to diseased portions of the lung, the Tokyo-based company said. The device is placed during a bronchoscopic procedure to reduce lung volume in diseased lung sections and allow healthier tissue in the remaining portion of the lung to function better. Approval of the device came based on the results from the Emprove clinical trial of the SV...
Source: Mass Device - December 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Regulatory/Compliance Respiratory Olympus Source Type: news

Olympus Spiration(R) Valve System Is FDA Approved for the Endobronchial Treatment of Emphysema
Minimally invasive therapy offers non-invasive patient screening with short procedure time and is shown to improve lung function and quality of life CENTER VALLEY, Pa., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Olympus, a global technol... Devices, FDA Olympus Medical Systems, Spiration Valve, Emphysema, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Pulmonx wins Aetna coverage for Zephyr endobronchial valve
Pulmonx said yesterday that it won national coverage through health insurer Aetna for its Zephyr endobronchial valve system intended for treating severe emphysema and chronic obstructive pulmonary disorder. The coverage will make the Zephyr valve available to Aetna’s 22 million members, the Redwood City, Calif.-based company said. Under its new policy, Aetna specifically named the Zephyr as an approved bronchoscopic option for lung volume reduction, considering it medically necessary for the broncoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung with littl...
Source: Mass Device - November 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Respiratory Pulmonx Source Type: news

Banner University Medicine first in Arizona to offer new option for patients with severe COPD/emphysema
(Pulmonx) Banner University Medicine Lung Institute is the first in Arizona and second in the US to offer a new lung valve treatment for patients with severe COPD or emphysema. Recently approved by the FDA under their 'Breakthrough Devices' designation, the Zephyr ® Endobronchial Valve system is a major advancement in treatment because it is the first minimally invasive procedure to help emphysema sufferers breathe easier without major surgery. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - November 12, 2018 Category: International Medicine & Public Health Source Type: news

Gala Therapeutics launches RheOx chronic bronchitis trial
Gala Therapeutics said today that it launched an early feasibility study of its RheOx system for treating chronic bronchitis, and that the first two patients in the trial have already been enrolled. Initial patient enrollment took place at the University of Pittsburgh Medical Center, with RheOx bronchial rheoplasty procedures performed by Dr. Frank Sciurba and Roy Semaan, the Menlo Park, Calif.-based company said. “We are pleased to partner with Gala in treating the first US patients and thus continuing the contribution of UPMC as a leader in the development of novel devices for our patients with COPD. RheOx off...
Source: Mass Device - November 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Respiratory galatherapeutics Source Type: news

ANI Announces Launch of Authorized Generic of Brethine(R)
BAUDETTE, Minn., Oct. 16, 2018 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. Th... Biopharmaceuticals, Generics, Product Launch ANI Pharmaceuticals, Terbutaline, Brethine, bronchitis, emphysema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 16, 2018 Category: Pharmaceuticals Source Type: news

Smoking Seems to Weaken the Immune System: Study
TUESDAY, Oct. 2, 2018 -- The list of health risks linked to smoking continues to grow. A small study reports that, aside from lung cancer, emphysema and heart disease, cigarette smokers also have weakened immune systems affecting their dental... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 2, 2018 Category: General Medicine Source Type: news

A New Definition for Emphysema A New Definition for Emphysema
A new study has identified a clinically relevant definition for emphysema using CT imaging.Medscape Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 27, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Viewpoint Source Type: news

Zapping Airway Nerves May Help COPD Patients
COPD, which is often linked to smoking, is a progressive deterioration of lung function that involves a combination of bronchitis and emphysema symptoms. (Source: WebMD Health)
Source: WebMD Health - September 18, 2018 Category: Consumer Health News Source Type: news

New Bronchoscopic Option Used for Severe Emphysema
First bronchoscopic lung volume reduction using endobronchial valve performed at Temple University (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 10, 2018 Category: Respiratory Medicine Tags: Pulmonology, Surgery, Institutional, Source Type: news

BTG Intensifies Focus on Pulmonary Embolism Through Acquisition
BTG is busy on the M&A trail today. The London-based company has acquired Novate Medical, a firm focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events, for $20 million in cash with an additional $130 million in milestones. Novate Medical has developed Sentry, a bioconvertible inferior vena cava (IVC) filter, which has recently been granted 510(k) regulatory clearance. Sentry’s 12-month clinical trial data demonstrated no new symptomatic PE and no evidence of device migration, tilt, fracture, perforation or embolization, complications which have b...
Source: MDDI - September 10, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

New Bronchoscopic Option Used for Severe Emphysema
MONDAY, Sept. 10, 2018 -- Temple University Hospital has become the first center in the U.S. to perform bronchoscopic lung volume reduction using implantation of the Zephyr Endobronchial Valve (Zephyr EBV) to treat hyperinflation associated with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2018 Category: Pharmaceuticals Source Type: news

NIH study broadens understanding of High Impact Chronic Pain in the US
Researchers have demonstrated that disability is as likely in the chronic pain population as it is in those with kidney failure, emphysema or stroke. This is the reality for 11 million U.S. adults with High Impact Chronic Pain (HICP), a new concept that describes those with pain lasting three months or longer and accompanied by at least one major activity restriction. (Source: NCCAM Featured Content)
Source: NCCAM Featured Content - September 5, 2018 Category: Complementary Medicine Authors: NCCIH Source Type: news

Temple University Hospital performs nation's 1st post-FDA approval BLVR using Zephyr Valve
(Temple University Health System) Temple University Hospital has become the first US center to perform bronchoscopic lung volume reduction using implantation of the Zephyr ® Endobronchial Valve (Zephyr ® EBV ® ) to treat severe emphysema following US FDA approval. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 20, 2018 Category: International Medicine & Public Health Source Type: news

FDA: Zephyr Endobronchial Valve Approved for Severe Emphysema
FRIDAY, July 6, 2018 -- A new device, the Zephyr Endobronchial Valve (Zephyr Valve), has been approved by the U.S. Food and Drug Administration for the treatment of breathing difficulties associated with severe emphysema. During a procedure in a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 6, 2018 Category: Pharmaceuticals Source Type: news

Redwood City company wins FDA approval for emphysema-treating medical device
For patients with severe emphysema, the new technology allows for treatment of the chronic disease without major invasive surgery. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 5, 2018 Category: Pharmaceuticals Authors: Kevin Truong Source Type: news

Redwood City company wins FDA approval for emphysema-treating medical device
For patients with severe emphysema, the new technology allows for treatment of the chronic disease without major invasive surgery. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 5, 2018 Category: Biotechnology Authors: Kevin Truong Source Type: news

How a New Emphysema Device Won FDA Approval in Six Months
FDA has approved a new device intended to treat breathing difficulty associated with severe emphysema. The approval comes just two weeks after an FDA advisory panel shot down a competing technology targeting the same patient population. The agency approved Pulmonx Inc.'s Zephyr endobronchial valve through the breakthrough device designation, a pathway reserved for devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. Devices also must meet one of the following criteria: the device must represent a breakthrough technology; there must be no app...
Source: MDDI - July 2, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

FDA Clears Zephyr Endobronchial Valve to Treat Severe Emphysema FDA Clears Zephyr Endobronchial Valve to Treat Severe Emphysema
The Zephyr valve is the first minimally invasive device approved in the US for treating patients with severe emphysema.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

FDA Approves Novel Device for Treating Breathing Difficulty from Severe Emphysema
June 29, 2018 -- The U.S. Food and Drug Administration today approved a new device, the Zephyr Endobronchial Valve (Zephyr Valve), intended to treat breathing difficulty associated with severe emphysema. “Treatment options are limited for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 29, 2018 Category: Pharmaceuticals Source Type: news

FDA approves novel device for treating breathing difficulties associated with severe emphysema- https://go.usa.gov/xUYXd   #FDA #MedicalDevice #COPDpic.twitter.com/do1EG38wMM
FDA approves novel device for treating breathing difficulties associated with severe emphysema- https://go.usa.gov/xUYXd  #FDA #MedicalDevice #COPD pic.twitter.com/do1EG38wMM (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - June 29, 2018 Category: Medical Devices Authors: ( at FDADeviceInfo) Source Type: news

Pulmonx wins FDA approval for Zephyr endobronchial valve
The FDA today granted pre-market approval under its breakthrough devices designation to the Zephyr endobronchial valve made by Pulmonx for treating severe emphysema. Emphysema, a chronic obstructive pulmonary disease, causes irreversible damage to the lung’s alveoli, trapping air during exhalation that in turn can cause the diseased tissue to grow larger and pressure healthy lung tissue. The Zephyr device is designed to decrease the volume of the chest to improve function in the heart, respiratory muscles and healthy lung tissue. Inserted via bronchoscopy, the pencil-eraser-sized valves prevent air from ent...
Source: Mass Device - June 29, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Endoscopic / Arthroscopic Food & Drug Administration (FDA) Regulatory/Compliance Respiratory Pulmonx Source Type: news

FDA approves novel device for treating breathing difficulty from severe emphysema
(Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2018 Category: American Health Source Type: news

FDA Panel Shoots Down Endobronchial Coil System – Is the Device Doomed?
    BTG plc (LSE: BTG), the global specialist healthcare company, notes that the US Food & Drug Administration’s (FDA’s) Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee yesterday voted against the approval of the Elevair™ Endobronchial Coil System for the treatment of people with severe emphysema. The Panel voted as follows: that there is reasonable assurance that Elevair™ is safe for use in patients who meet the criteria specified in the proposed indication, while considering the additional procedures needed to maintain effectiv...
Source: MDDI - June 18, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Business Source Type: news

FDA panel votes against BTG ’ s PneumRX Elevair
An FDA advisory committee panel yesterday voted against approving BTG‘s PneumRX’s Elevair endobronchial coil system intended for treating patients with severe emphysema. The panel voted 7 to 5 in favor of the device’s safety, but 8 to 3 that the benefits do not outweigh the risks, and 5 to 7 that the device was effective for use with patients in its proposed indications. The Elevair device is a nitinol endobronchial coil intended to be deployed bronchoscopically to reduce lung volume in patients with severe emphysema. The company submitted an application for premarket approval with the FDA, backed by clin...
Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Respiratory BTG Source Type: news

Emphysema from Crack Cocaine?
Title: Emphysema from Crack Cocaine?Category: Doctor's& Expert's views on SymptomsCreated: 6/24/2008 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:06 PM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - June 13, 2018 Category: Respiratory Medicine Source Type: news

Endobronchial-Valve Treatment Improves Lung Function in Emphysema Endobronchial-Valve Treatment Improves Lung Function in Emphysema
Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 29, 2018 Category: Surgery Tags: Pulmonary Medicine News Source Type: news

Pulmonx Closing in On Approval for Valve to Treat Emphysema
Pulmonx has some additional ammunition in its bid to get its severe emphysema treatment valve FDA approval. The Redwood City, CA-based company released positive one-year-results from the LIBERATE pivotal trial of the Zephyr Endobronchial Valve, which shows the study met all primary and secondary endpoints in treating emphysema patients. Emphysema falls under the umbrella of chronic obstructive pulmonary disease (COPD) and is characterized by damage to the walls of the lungs between the air sacs, according to the National Emphysema Foundation. This damage causes the sacs to lose their shape and often, the destruction of tho...
Source: MDDI - May 25, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Pulmonx touts quality of life, lung function improvements in 1-year Zephyr endobronchial valve IDE study
This study was the largest, longest study to use a less-invasive or minimally-invasive technique using these one-way valves,” Dr. Criner said. Dr. Criner said that after one year, patients treated with the Zephyr valves were significnatly more likely to show improvements in lung function, measured as forced expiratory volume in one second, or FEV1. “Patients that were treated had about a three times greater likelihood of having significant improvement in FEV1, more than 15% in 45% of the treated group compared to 11% of the control,” Dr. Criner said. Additionally, patients treated with the Zephyr reported...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Respiratory Pulmonx Source Type: news

Medical News Today: What to know about centrilobular emphysema
Centrilobular emphysema is a form of emphysema where the damage begins in the central lobes of the lungs and spreads outward. This is distinct from panlobular emphysema. In this article, we discuss centrilobular emphysema including symptoms, causes, complications, and possible treatments. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 22, 2018 Category: Consumer Health News Tags: COPD Source Type: news

What Are Complications of Oropharyngeal Trauma?
Discussion Oropharyngeal trauma is common and ranges from minor contusions to severe trauma of the head and neck. Sudden movement while having a foreign object in the mouth is a very common scenario with falls or collisions being common mechanisms. Common objects include toys, sticks, pens/pencils, chopsticks, toothbrushes, and popsicle sticks. Many of these injuries cause minimal problems such as a contusion to lips (i.e. “fat lip”). In general, the more anterior the location the more common the injury and the less likely to have a severe injury (i.e. lips). Whereas posterior structures are more protected, bu...
Source: PediatricEducation.org - April 16, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Say what? Smoking found to increase risk of hearing loss, according to study
(Natural News) Still dying for a smoke? Besides, emphysema, diabetes, rheumatoid arthritis, blindness and of course cancer, here’s one more reason to stop smoking  — hearing loss. A recently-published study published by Oxford University Press showed that the more than 50,000 participants of the over eight year-study showed that “smoking is an independent risk factor... (Source: NaturalNews.com)
Source: NaturalNews.com - April 10, 2018 Category: Consumer Health News Source Type: news

5 Key Takeaways from Mesothelioma Expert Teleconference
If you have been diagnosed with mesothelioma, you’re likely seeking information and resources to learn more about the disease. A free one-hour mesothelioma teleconference is a great place to start. CancerCare recently hosted the “Advancements in the Treatment of Mesothelioma” workshop. The session featured five mesothelioma experts, including Dr. Hedy Kindler, director of the mesothelioma program at the University of Chicago Comprehensive Cancer Center. The Mesothelioma Applied Research Foundation co-sponsored the teleconference, which is available online for free. All mesothelioma patients can benefit f...
Source: Asbestos and Mesothelioma News - April 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Ask Have Emphysema Without Being a Smoker
Can You Have Emphysema Without Being a Smoker? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 3, 2018 Category: General Medicine Source Type: news

EBV treatment cost  effective for severe emphysema
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2018 Category: Drugs & Pharmacology Source Type: news

Pulmonary Edema vs Emphysema
Pulmonary Edema vs. Emphysema (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 8, 2018 Category: General Medicine Source Type: news

Zebra Medical wins CE Mark for brain-bleed detection algorithm
Israeli machine-learning radiology firm Zebra Medical Vision said today it won CE Mark approval in the European Union for an algorithm for detecting intracranial hemorrhages as part of its deep learning imaging analytics platform. Zebra Medical said that its algorithm is designed to identify brain bleeds to provide extra support for physicians in acute care settings, and that it plans to use the algorithm for point-of-care detection to identify bleeds accurately and with reduced delay. “This new algorithm is an important addition to Zebra’s Analytics Engine. The ability to alert radiologists and surgeons t...
Source: Mass Device - March 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Neurological Regulatory/Compliance Software / IT Zebra Medical Vision Source Type: news

Widely Used COPD Meds Tied to Higher Fracture Risk
COPD -- often linked to smoking -- is a combination of emphysema and chronic bronchitis. It is a progressive, debilitating illness that currently has no cure. (Source: WebMD Health)
Source: WebMD Health - February 13, 2018 Category: Consumer Health News Source Type: news

Former S.D. dentist pleads guilty to $17m medtech fraud scheme
A former dentist from South Dakota plead guilty last week to a $16.6 million scheme to defraud consumers through the sale of a sham laser device and associated treatments, promising it would cure more than 200 different conditions, according to a US Department of Justice report. The plea was the finale to a three-year effort from the DoJ to halt the distribution of the device, known as the “QLaser System”, according to the report. The defendant, 82-year-old Robert Lytle of Rapid City, S.D., plead guilty to a single count of conspiracy to introduce misbranded medical devices into interstate commerce with the int...
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Legal News Regulatory/Compliance U.S. Justice Dept. (DOJ) Source Type: news